TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: change in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pH level of exhaled breath condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: robustness of d-dimer testing for PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 8-isoprostane level in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Recovery in Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Initial Decrement in Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Response rate pre-radiation chemotherapy and bevacizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment late loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Metastasis Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Control of pain after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of ibuprofen in human mature milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of ketoprofen in human mature milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biochemical hyperandrogenism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of Colonoscopy Preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's height and weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival at 48 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: EVA pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of major bleeding, recurrent ischaemic stroke, systemic embolism and/or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Dermal Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic yield rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Competitive employment or education
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Fugl-Meyer (FM) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in parent weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed Standard Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Primary performance patient assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of men failing to return for a post-operative clinic visit at 7 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of men who report resumption of sexual activity before 42 days post-circumcision
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical Component Summary Score (PCS) of Short-Form 36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of coronary vulnerable plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normalized peak relaxation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (zero to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma acetate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: relative permeability coefficients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Develop Desensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of infections related to chamber implantable catheters
Endpoint domain: Adverse events/effects
Primary endpoint: Skin condition score of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Neutrophil Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum glycan biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease Recurrence Rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of planned patients receiving treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Orthodontic root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac output variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stabilizing overall neurocognitive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Natural history of neuroendocrine neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the number of leakages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Brain regional gray matter density change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain functional connectivity strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Subjects With Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: post-irradiation erythema severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ad libitum meal intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) for Pyrazinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) for Pyrazinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number (%) of Subjects With Drug Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory Tests
Endpoint domain: Adverse events/effects
Primary endpoint: Number (%) of Subjects With Clinically Relevant Abnormalities in Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Prematurely Discontinuing Due to a TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Evidence-based practice questionnaire (EBP2Q)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: QIDS-SR16 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Q-LES-Q-SF score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the concentration-time curve over one dosing interval (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum observed concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral clearance (Dose/AUC) at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drug Liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of tamoxifen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly Rate of Change in Abstinent Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Results of clinical assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of imaging assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the-plasma-concentration-curve (AUC) of 7-ketocholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in disease state characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spastic co-contraction index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Tissue penetration distance of cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amount of Bone Density Lost (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response to the Mixed Meal Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Somatic Growth (Weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Somatic Growth (Length)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Somatic Growth (Head Circumference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in use of food resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SARS-Cov2 viral load in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in forced expiratory volume at one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to return to final work status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cannabis Craving Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cannabis Attention Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Marijuana Craving Questionnaire-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Graded Change in Dermatochalasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of correcting desaturation during effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acceptance of oxygen conserving devices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hearing function protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LCPUFA loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation between biomarkers and breath components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sequential Organ Failure Assessment score (SOFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experience Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Total Volume of Distribution (VT) of [18F]PGM299 in the Cerebellar Grey Matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-displaceable Binding Potential (BPND) of [18F]PGM299 in the Cerebellar Grey Matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: D-amino Acid Oxidase (DAO) Occupancy Estimation in the Cerebellar Grey Matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in visual analogue score (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's Subjective Rating for Overall Satisfaction - Comfort
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Change in Number of Raynaud Attacks Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Average Duration of Fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in IBS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUCt of Memantine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Memantine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in renal clearance of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean trough steady-state concentrations of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Freedom From Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Total Atheroma Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Conscious level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Retract-and-Reorder (RAR) events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of disordered eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate molecular response to activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate physiological response to activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Treatment Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Score (PATIENT HEALTH QUESTIONNAIRE [PHQ] 9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interfraction reproducibility of chest wall position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in mean left anterior descending coronary artery (LAD) mean normal tissue dose (NTDmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: participants rating of worst pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Breast milk eltrombopag concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of the restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CD45+ cells expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Consistency of EGFR mutation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid intraplaque hemorrhage correlation with carotid plaque inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid MRI-detected intraplaque hemorrhage and prediction of brain inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of cognitive improvement after endarterectomy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression-Free Survival (PFS) Rate at Six Months
Endpoint domain: Mortality/survival
Primary endpoint: Percent change in Yale Global Tic Severity Scale (YGTSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of thrombotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of haemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Global Impression of Change for Knee Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain level with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Involvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Persistence of daily meditation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in binocular vision test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Nonmyeloablative Preparative Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neutrophil count <500/mcL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Global Impression-Improvement (CGI-I) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommended dose for future trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Moderate to Vigorous Physical Activity (minutes / day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedentary Behavior (hours / day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in learning rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of win-driven choices
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients with disease or death
Endpoint domain: Mortality/survival
Primary endpoint: Hepatic encephalopathy severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in coping ability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive decline measured by MMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive decline measured by TEGEST test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive decline measured by Clock drawing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in Vibration Perception Threshold (VPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in center of pressure displacement (balance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased Arterial Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urine retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: qCON monitoring during maintenance of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rate of change in area of GA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroprotective effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: biological efficacy of tailored clopidogrel therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of developing diabetic foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of myocardial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients who have access to and ability to use smart devices and the internet
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients aware of mHealth Services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients who currently use or would use mHealth services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Histological change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injury associated infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Post-prandial satiety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: photoplethysmographic waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes